Filing Details
- Accession Number:
- 0001567619-19-001609
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-01-24 19:48:04
- Reporting Period:
- 2019-01-22
- Accepted Time:
- 2019-01-24 19:48:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1348911 | Kalvista Pharmaceuticals Inc. | KALV | Pharmaceutical Preparations (2834) | 200915291 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1691102 | Christopher Yea | C/O Kalvista Pharmaceuticals, Inc. 55 Cambridge Parkway, Suite 901E Cambridge MA 02142 | Chief Development Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-01-22 | 1,302 | $0.00 | 84,271 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-01-22 | 1,302 | $17.00 | 82,969 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-01-23 | 600 | $0.00 | 83,569 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-01-23 | 600 | $17.01 | 82,969 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2019-01-22 | 1,302 | $0.00 | 1,302 | $0.00 |
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2019-01-23 | 600 | $0.00 | 606 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 115,508 | 2026-03-30 | No | 4 | M | Direct | |
| 114,908 | 2026-03-30 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.01 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.03 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- This option is 100% vested and exercisable.
Billionaire Hedge Funds
